These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1957557)

  • 1. Prolactinoma and body weight: a retrospective study.
    Creemers LB; Zelissen PM; van 't Verlaat JW; Koppeschaar HP
    Acta Endocrinol (Copenh); 1991 Oct; 125(4):392-6. PubMed ID: 1957557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased prevalence of high Body Mass Index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma.
    Schmid C; Goede DL; Hauser RS; Brändle M
    Swiss Med Wkly; 2006 Apr; 136(15-16):254-8. PubMed ID: 16708311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative analysis of surgical and medical treatment of macroprolactinoma of different localization].
    Astaf'eva LI; Kadashev BA; Dedov II; Kalinin PL; Kutin MA; Shkaburo AN; Fomichev DV; Tenedieva VD; Tropinskaia OF
    Zh Vopr Neirokhir Im N N Burdenko; 2011; 75(4):3-9; discussion 9. PubMed ID: 22379847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas?
    Yermus R; Ezzat S
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):562. PubMed ID: 11966752
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolactinoma in childhood and adolescence-Tumour size at presentation predicts management strategy: Single centre series and a systematic review and meta-analysis.
    Arya VB; Aylwin SJB; Hulse T; Ajzensztejn M; Kalitsi J; Kalogirou N; Bodi I; Thomas N; Hampton T; Kapoor RR; Buchanan CR
    Clin Endocrinol (Oxf); 2021 Mar; 94(3):413-423. PubMed ID: 33340135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
    Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Some issues in the diagnosis and treatment of hyperprolactinemia].
    Jin ZM
    Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):241-3. PubMed ID: 18843959
    [No Abstract]   [Full Text] [Related]  

  • 9. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy.
    Kim D; Ku CR; Kim K; Jung H; Lee EJ
    Eur J Endocrinol; 2020 Feb; 182(2):177-183. PubMed ID: 31770105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.
    Araújo C; Marques O; Almeida R; Santos MJ
    Endocrine; 2018 Nov; 62(2):470-476. PubMed ID: 30088141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma.
    Aboelnaga MM; Abdullah N; El Shaer M
    Endocr Metab Immune Disord Drug Targets; 2017; 17(3):219-225. PubMed ID: 28595559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatments of multi-invasive giant prolactinoma.
    Yang MY; Shen CC; Ho WL
    J Clin Neurosci; 2004 Jan; 11(1):70-5. PubMed ID: 14642373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
    Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance and androgen levels in eugonadic and hypogonadic women with prolactinoma.
    Dogan BA; Berker D; Arduc A; Tuna MM; Nasiroglu NI; Karakiliç E; Basaran MN; Isik S; Tutuncu Y; Unal M; Guler S
    Minerva Endocrinol; 2016 Jun; 41(2):175-82. PubMed ID: 25288097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant prolactinoma.
    Berezin M; Gutman I; Tadmor R; Horowitz A; Findler G
    Acta Endocrinol (Copenh); 1992 Nov; 127(5):476-80. PubMed ID: 1471460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual vignette. Macroprolactinoma.
    Orrego JJ
    Endocr Pract; 2008 Apr; 14(3):393. PubMed ID: 18463052
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas.
    Maraschini C; Moro M; Masala A; Toja P; Alagna S; Brunani A; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):494-501. PubMed ID: 1759539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
    Passos VQ; Souza JJ; Musolino NR; Bronstein MD
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3578-82. PubMed ID: 12161478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.